William P Schiemann

List of Publications by Year
in descending order

79 papers	8,429 citations	57758 44 h-index	69250 77 g-index
80 all docs	80 docs citations	80 times ranked	11923 citing authors

#	Article	IF	Citations
1	Telomerase in Cancer: Function, Regulation, and Clinical Translation. Cancers, 2022, 14, 808.	3.7	30
2	Preclinical Development of the Class-Iâ€"Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 397-406.	4.1	8
3	The role of RNA processing and regulation in metastatic dormancy. Seminars in Cancer Biology, 2021, , .	9.6	5
4	SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-Î°B and Notch signaling. Science Signaling, 2021, 14, .	3.6	17
5	lncRNA BORG:TRIM28 Complexes Drive Metastatic Progression by Inducing Î±6 Integrin/CD49f Expression in Breast Cancer Stem Cells. Molecular Cancer Research, 2021, 19, 2068-2080.	3.4	9
6	Epigenetic plasticity in metastatic dormancy: mechanisms and therapeutic implications. Annals of Translational Medicine, 2020, 8, 903-903.	1.7	10
7	Epithelialâ€"Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Molecular Cancer Research, 2020, 18, 1257-1270.	3.4	86
8	SLX4IP and telomere dynamics dictate breast cancer metastasis and therapeutic responsiveness. Life Science Alliance, 2020, 3, e201900427.	2.8	17
9	Introduction to this special issue â€œBreast Cancer Metastasisâ€. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	1
10	Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature Communications, 2019, 10, 3668.	12.8	103
11	Effective treatment of cancer metastasis using a dual-ligand nanoparticle. PLoS ONE, 2019, 14, e0220474.	2.5	21
12	Autophagy in breast cancer metastatic dormancy: tumor suppressing or tumor promoting functions?. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	24
13	Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	10
14	A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity. PLoS Biology, 2019, 17, e3000204.	5.6	15
15	Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy. Bioconjugate Chemistry, 2019, 30, 907-919.	3.6	121
16	The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene, 2019, 38, 2020-2041.	5.9	70
17	The lncRNA BORG: a novel inducer of TNBC metastasis, chemoresistance, and disease recurrence. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	9
18	Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 68.	3.0	14

#	Article	IF	Citations
19	Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1â€“Mediated Macrophage Infiltration. Cancer Research, 2017, 77, 5129-5141.	0.9	52
20	Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers. Cell Death and Disease, 2017, 8, e2899-e2899.	6.3	16
21	The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin. Stem Cell Investigation, 2017, 4, 44-44.	3.0	1
22	The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence. Scientific Reports, 2017, 7, 12698.	3.3	73
23	The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer. Oncotarget, 2017, 8, 104072-104089.	1.8	25
24	TGF-Î² stimulation of EMT programs elicits non-genomic ER-Î± activity and anti-estrogen resistance in breast cancer cells. Journal of Cancer Metastasis and Treatment, 2017, 3, 150.	0.8	43
25	Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Management and Research, 2016, 8, 21.	1.9	9
26	Transforming Growth Factor-Î² Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2â€“Dependent Bladder Cancer Cell Migration and Invasion. American Journal of Pathology, 2016, 186, 1351-1360.	3.8	33
27	Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 320-329.	7.4	17
28	c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget, 2016, 7, 72777-72794.	1.8	17
29	Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Translational Cancer Research, 2016, 5, S226-S232.	1.0	5
30	Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples. Recent Patents on Biomarkers, 2016, 5, 93-100.	0.2	14
31	Tipping the balance between good and evil: aberrant 14-3-3Î¶ expression drives oncogenic TGF-Î² signaling in metastatic breast cancers. Breast Cancer Research, 2015, 17, 92.	5.0	3
32	Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression. Neoplasia, 2015, 17, 317-328.	5.3	58
33	Silencing Î²3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2015, 75, 2316-2325.	0.9	135
34	Non-muscle myosin IIB is critical for nuclear translocation during 3D invasion. Journal of Cell Biology, 2015, 210, 583-594.	5.2	116
35	ECO/siRNA nanoparticles and breast cancer metastasis. Oncoscience, 2015, 2, 823-824.	2.2	0
36	STAT3 and epithelialâ€“mesenchymal transitions in carcinomas. Jak-stat, 2014, 3, e28975.	2.2	151

#	Article	IF	Citations
37	Therapeutic opportunities for targeting microRNAs in cancer. Molecular and Cellular Therapies, 2014, 2, 30.	0.2	36
38	Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1Î±-mediated angiogenesis. Jak-stat, 2014, 3, e1009276.	2.2	16
39	Chemotherapeutic targeting of the TGF-Î² pathway in breast cancers. Breast Cancer Management, 2014, 3, 73-85.	0.2	6
40	WAVE3-NFÎºB Interplay Is Essential for the Survival and Invasion of Cancer Cells. PLoS ONE, 2014, 9, e110627.	2.5	22
41	Upregulated WAVE3 expression is essential for TGF-Î²-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Research and Treatment, 2013, 142, 341-353.	2.5	54
42	Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Research, 2013, 15, R72.	5.0	52
43	Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway. Journal of Biological Chemistry, 2013, 288, 17954-17967.	3.4	118
44	The relevance of the TGF-Î² Paradox to EMT-MET programs. Cancer Letters, 2013, 341, 30-40.	7.2	174
45	Targeted inactivation of Î²1 integrin induces Î²3 integrin switching, which drives breast cancer metastasis by TGF-Î². Molecular Biology of the Cell, 2013, 24, 3449-3459.	2.1	84
46	TGF-Î² upregulates miR-181a expression to promote breast cancer metastasis. Journal of Clinical Investigation, 2013, 123, 150-163.	8.2	264
47	The Multifunctional Roles of TGF-Î² in Navigating the Metastatic Cascade. , 2013, , 169-187.		0
48	Deconstructing the mechanisms and consequences of TGF-Î²-induced EMT during cancer progression. Cell and Tissue Research, 2012, 347, 85-101.	2.9	202
49	Lysyl Oxidase Contributes to Mechanotransduction-Mediated Regulation of Transforming Growth Factor-Î² Signaling in Breast Cancer Cells. Neoplasia, 2011, 13, 406-IN2.	5.3	85
50	Role of TGF-Î² and the Tumor Microenvironment During Mammary Tumorigenesis. Gene Expression, 2011, 15, 117-132.	1.2	81
51	Transforming growth factor-Î² and the hallmarks of cancer. Cellular Signalling, 2011, 23, 951-962.	3.6	218
52	Noncanonical TGF-Î² Signaling During Mammary Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 127-146.	2.7	103
53	Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Molecular Biology of the Cell, 2011, 22, 2423-2435.	2.1	162
54	Î²3 Integrinâ€“EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Molecular Biology of the Cell, 2011, 22, 4288-4301.	2.1	34

#	Article	IF	Citations
55	Homeoprotein Six1 Increases TGF-Î² Type I Receptor and Converts TGF-Î² Signaling from Suppressive to Supportive for Tumor Growth. Cancer Research, 2010, 70, 10371-10380.	0.9	101
56	The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-Î² in Normal and Malignant Mammary Epithelial Cells. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 169-190.	2.7	202
57	PGE2 receptor EP2 mediates the antagonistic effect of COXâ€2 on TGFâ€Î² signaling during mammary tumorigenesis. FASEB Journal, 2010, 24, 1105-1116.	0.5	62
58	p130Cas Is Required for Mammary Tumor Growth and Transforming Growth Factor-Î²-mediated Metastasis through Regulation of Smad2/3 Activity. Journal of Biological Chemistry, 2009, 284, 34145-34156.	3.4	62
59	Mechanisms of the epithelialâ€"mesenchymal transition by TGF-Î². Future Oncology, 2009, 5, 1145-1168.	2.4	290
60	X-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-Î²-mediated Nuclear Factor-ÎºB Activation during Breast Cancer Progression. Journal of Biological Chemistry, 2009, 284, 21209-21217.	3.4	46
61	Activated Abl kinase inhibits oncogenic transforming growth factorâ€Î² signaling and tumorigenesis in mammary tumors. FASEB Journal, 2009, 23, 4231-4243.	0.5	56
62	The TGF-Î² paradox in human cancer: an update. Future Oncology, 2009, 5, 259-271.	2.4	187
63	Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-Î² signaling and metastasis. Breast Cancer Research, 2009, 11, R68.	5.0	143
64	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-Î² signaling. Journal of Clinical Investigation, 2009, 119, 2678-2690.	8.2	209
65	Grb2 binding to Tyr284 in TÎ²R-II is essential for mammary tumor growth and metastasis stimulated by TGF-Î². Carcinogenesis, 2008, 29, 244-251.	2.8	74
66	Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-Â in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis, 2008, 29, 2243-2251.	2.8	132
67	Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-Â through a PGE2-dependent mechanisms. Carcinogenesis, 2008, 29, 2227-2235.	2.8	153
68	Altered TAB1:IÎºB Kinase Interaction Promotes Transforming Growth Factor Î²â€"Mediated Nuclear Factor-ÎºB Activation during Breast Cancer Progression. Cancer Research, 2008, 68, 1462-1470.	0.9	81
69	Src Phosphorylates Tyr284 in TGF-Î² Type II Receptor and Regulates TGF-Î² Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion. Cancer Research, 2007, 67, 3752-3758.	0.9	223
70	Targeted TGF-Î² chemotherapies: friend or foe in treating human malignancies?. Expert Review of Anticancer Therapy, 2007, 7, 609-611.	2.4	23
71	Î²3Integrin and Src facilitate transforming growth factor-Î² mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 2006, 8, R42.	5.0	216
72	Role of transforming growth factor-Î² in cancer progression. Future Oncology, 2006, 2, 743-763.	2.4	81

#	Article	IF	Citations
73	Transforming growth factor-Î² (TGF-Î²)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-Î² receptor. Cancer Detection and Prevention, 2004, 28, 57-64.	2.1	29
74	Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor beta signaling. BMC Cell Biology, 2004, 5, 2.	3.0	37
75	Cystatin C Antagonizes Transforming Growth Factor Î² Signaling in Normal and Cancer Cells. Molecular Cancer Research, 2004, 2, 183-195.	3.4	113
76	Context-specific Effects of Fibulin-5 (DANCE/EVEC) on Cell Proliferation, Motility, and Invasion. Journal of Biological Chemistry, 2002, 277, 27367-27377.	3.4	141
77	TGF-Î²-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nature Cell Biology, 2001, 3, 708-714.	10.3	332
78	Role of Transforming Growth Factor Î² in Human Disease. New England Journal of Medicine, 2000, 342, 1350-1358.	27.0	2,264
79	A Deletion in the Gene for Transforming Growth Factor Î² Type I Receptor Abolishes Growth Regulation by Transforming Growth Factor Î² in a Cutaneous T-Cell Lymphoma. Blood, 1999, 94, 2854-2861.	1.4	123